Total Payments
$6,767
2024 Payments
$988.61
Companies
51
Transactions
359
Medicare Patients
1,709
Medicare Billing
$193,841
Payment Breakdown by Category
Food & Beverage$6,432 (95.0%)
Education$335.36 (5.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,432 | 347 | 95.0% |
| Education | $335.36 | 12 | 5.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $922.10 | 62 | $0 (2024) |
| Seagen Inc. | $554.30 | 24 | $0 (2023) |
| PFIZER INC. | $517.13 | 28 | $0 (2024) |
| Genentech USA, Inc. | $425.92 | 25 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $393.11 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $385.52 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $380.79 | 26 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $208.35 | 12 | $0 (2023) |
| Amgen Inc. | $199.04 | 7 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $195.26 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $988.61 | 40 | PFIZER INC. ($162.16) |
| 2023 | $533.88 | 24 | Seagen Inc. ($270.09) |
| 2022 | $266.88 | 15 | Pharmacyclics LLC, an AbbVie Company ($65.33) |
| 2021 | $503.14 | 27 | Seagen Inc. ($193.01) |
| 2020 | $477.75 | 28 | Takeda Pharmaceuticals U.S.A., Inc. ($89.02) |
| 2019 | $1,485 | 86 | E.R. Squibb & Sons, L.L.C. ($333.97) |
| 2018 | $1,473 | 78 | E.R. Squibb & Sons, L.L.C. ($285.77) |
| 2017 | $1,039 | 61 | E.R. Squibb & Sons, L.L.C. ($238.57) |
All Payment Transactions
359 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: Genetic Disease | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/30/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.29 | General |
| Category: Hematology | ||||||
| 10/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $49.88 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $26.51 | General |
| 10/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $34.63 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.62 | General |
| 09/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.82 | General |
| Category: Hematology/Oncology | ||||||
| 08/20/2024 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.34 | General |
| Category: Hematology | ||||||
| 08/05/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $14.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Oncology | ||||||
| 07/09/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: HORMONE THERAPY | ||||||
| 06/20/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Rare Disease | ||||||
| 06/18/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: Oncology | ||||||
| 06/11/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Hematology | ||||||
| 06/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 335 | 565 | $158,924 | $42,851 |
| 2022 | 9 | 421 | 758 | $165,049 | $52,779 |
| 2021 | 7 | 396 | 662 | $131,649 | $47,109 |
| 2020 | 11 | 557 | 898 | $171,219 | $51,101 |
Total Patients
1,709
Total Services
2,883
Medicare Billing
$193,841
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 329 | $92,961 | $24,197 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 63 | $24,394 | $7,064 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 72 | $14,060 | $3,288 | 23.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 55 | $9,889 | $3,281 | 33.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 19 | $6,458 | $1,836 | 28.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,423 | $1,670 | 30.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,739 | $1,514 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 130 | 299 | $70,225 | $21,114 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 133 | 209 | $32,916 | $9,894 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 63 | $20,574 | $7,009 | 34.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 98 | $15,002 | $5,565 | 37.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 28 | 31 | $8,874 | $3,237 | 36.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $6,168 | $1,955 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $5,489 | $1,775 | 32.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $4,515 | $1,736 | 38.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 16 | $1,286 | $494.09 | 38.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 135 | 275 | $59,125 | $20,462 | 34.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 135 | 218 | $32,046 | $10,764 | 33.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 42 | $12,096 | $5,023 | 41.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 67 | $9,447 | $3,893 | 41.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 31 | 32 | $8,640 | $3,435 | 39.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $5,330 | $1,960 | 36.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $4,965 | $1,572 | 31.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 167 | 358 | $76,970 | $21,240 | 27.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 166 | 255 | $37,485 | $9,297 | 24.8% |
About Dr. Michael Andrews, MD
Dr. Michael Andrews, MD is a Hematology & Oncology healthcare provider based in Marietta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245234608.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Andrews, MD has received a total of $6,767 in payments from pharmaceutical and medical device companies, with $988.61 received in 2024. These payments were reported across 359 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($6,432).
As a Medicare-enrolled provider, Andrews has provided services to 1,709 Medicare beneficiaries, totaling 2,883 services with total Medicare billing of $193,841. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Marietta, GA
- Active Since 06/13/2005
- Last Updated 06/10/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1245234608
Products in Payments
- OPDIVO (Biological) $519.22
- ADCETRIS (Biological) $381.98
- KEYTRUDA (Biological) $322.58
- IMBRUVICA (Drug) $231.14
- EMPLICITI (Biological) $221.45
- TUKYSA (Drug) $197.02
- GILOTRIF (Drug) $193.33
- KISQALI (Drug) $162.87
- SOMATULINE DEPOT (Drug) $158.14
- Perjeta (Biological) $151.43
- LYNPARZA (Drug) $127.92
- PADCEV (Biological) $124.34
- REBLOZYL (Biological) $116.75
- IBRANCE (Drug) $103.36
- IMLYGIC (Biological) $102.77
- EPKINLY (Drug) $99.35
- KYPHON Balloon Kyphoplasty (Device) $97.84
- AMVUTTRA (Drug) $94.62
- MEKINIST (Drug) $92.54
- Imbruvica (Drug) $92.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Marietta
Dr. Steven Mccune, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $492,856
Hematology & Oncology $492,856
Dr. Gena Volas-Redd, Md, MD
Hematology & Oncology — Payments: $115,709
Hematology & Oncology $115,709
Dr. John French, Md, MD
Hematology & Oncology — Payments: $70,611
Hematology & Oncology $70,611
Dr. Louis Garrot, M.d, M.D
Hematology & Oncology — Payments: $57,738
Hematology & Oncology $57,738
Vivek Abhyankar, Md, MD
Hematology & Oncology — Payments: $53,680
Hematology & Oncology $53,680
Dr. Dean Kirkel, Md, MD
Hematology & Oncology — Payments: $53,593
Hematology & Oncology $53,593